HRTX Heron Therapeutics, Inc.

14.15
0  -1%
Previous Close 14.30
Open 14.30
Price To book 0.00
Market Cap N/A
Shares 0
Volume 504,004
Short Ratio 0.00
Av. Daily Volume 991,534

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Phase 3 trial to be initiated in 2017.
HTX-011
Hernia repair
Phase 2 data released August 2016
HTX-011
Bunionectomy
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
NDA filing announced January 12, 2017.
HTX-019
Prevention of chemotherapy-induced nausea and vomiting (CINV)

Latest News

  1. HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
  2. Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  3. Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : March 9, 2017
  4. HERON THERAPEUTICS, INC. /DE/ Financials
  5. Heron Therapeutics Inc (HRTX) Sustol To Be Included In Antiemesis Guidelines By NCCN
  6. Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference
  7. Coverage initiated on Heron Therapeutics by Needham
  8. Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines
  9. Heron Therapeutics reports 4Q loss
  10. Heron Therapeutics reports 4Q loss
  11. HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  12. Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress
  13. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  14. Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  15. LifeSci Capital Initiates Coverage of Heron Therapeutics
  16. Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares
  17. HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
  18. Heron Therapeutics Launches $150M Public Offering
  19. Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
  20. Heron Therapeutics Announces Proposed Public Offering of Common Stock